Consideration of Nebulized Lidocaine For Treatment of Covid19 Severity Via Targeting Neutrophil Extracellular Traps

Coronavirus disease 2019 (Covid19) is a viral-provoked respiratory disease that affects many patients worldwide. Clinical manifestations start with mild flu-like symptoms and progress to acute respiratory distress syndrome (ARDS), the trigger of which has been underpinned as cytokine storm. Neutrophil-derived neutrophil extracellular traps (NETs) greatly contribute to development of Covid19 severity. It has been hypothesized that nebulized lidocaine could be used to attenuate the severity of Covid19, however, the mechanism by which this may occur not completely clear. This review addresses the possibility of using nebulized lidocaine as a therapeutic approach for targeting Covid19-induced NETs formation.

Keywords: Covid19; Cytokines; Neutrophil; Neutrophil extracellular traps; Lung damage; Nebulized lidocaine

Abbreviations: Covid19-Coronavirus disease 2019; ARDS-Acute Respiratory Distress Syndrome; NETs-Neutrophil Extracellular Traps; SARSCoV- 2-Severe Acute Respiratory Syndrome Coronavirus 2; ACE2-9-Angiotensin Converting Enzyme 2; G-CSF-Granulocyte Colony Stimulating Factor; MCP1-Monocyte Chemoattractant Protein 1; STAT3-Signal Transducer And Activator of Transcription 3; CF Cystic Fibrosis; NE-Neutrophil Elastase